Polycythemia Vera (PV) is a rare, chronic blood cancer classified as a myeloproliferative neoplasm (MPN). It is characterized by the overproduction of red blood cells in the bone marrow. This increase in red blood cell mass leads to thickened blood (hyperviscosity), which raises the risk of blood clots (thrombosis) and can result in serious complications such as strokes or heart attacks.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Population of Polycythemia Vera
</li>
<li dir="ltr" aria-level="1">
Prevalent Population of Polycythemia Vera Based on Symptoms
</li>
<li dir="ltr" aria-level="1">
Gender-Specific Prevalence of Polycythemia Vera
</li>
<li dir="ltr" aria-level="1">
Prevalence of Polycythemia Vera by Gene Mutation
</li>
<li dir="ltr" aria-level="1">
Prevalence of Polycythemia Vera Based on Risk
</li>
<li dir="ltr" aria-level="1">
Age-Specific Prevalence of Polycythemia Vera
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/polycythemia-vera-epidemiology-forecast">Polycythemia Vera Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the total number of prevalent cases of Polycythemia Vera across the 7MM was estimated to be approximately 319,500, with this number expected to increase over the forecast period.
</li>
<li dir="ltr" aria-level="1">
The United States accounted for the largest share of PV prevalence among the 7MM, representing about 57% of the total cases in 2024.
</li>
<li dir="ltr" aria-level="1">
The EU4 (France, Germany, Italy, Spain) and the United Kingdom collectively made up roughly 32% of the total prevalent population, while Japan contributed approximately 11%.
</li>
<li dir="ltr" aria-level="1">
In the United States alone, there were an estimated 182,010 prevalent cases of Polycythemia Vera in 2024.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/polycythemia-vera-market">Polycythemia Vera Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The total market size for Polycythemia Vera across the 7MM was estimated at approximately USD 1.9 billion in 2024, with expectations for continued growth throughout the forecast period (2025&ndash;2034).
</li>
<li dir="ltr" aria-level="1">
Within the EU4 countries, Germany held the largest share of the PV market in 2024, while the United Kingdom represented the smallest market share during the same year.
</li>
<li dir="ltr" aria-level="1">
Among the currently available therapies for PV, JAKAFI generated the highest revenue in 2024, with approximately USD 965 million in sales in the United States alone.
</li>
</ul>
<h3 dir="ltr">Polycythemia Vera Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Improved awareness among healthcare professionals and patients is leading to earlier diagnosis and better disease monitoring, driving treatment demand.
</li>
<li dir="ltr" aria-level="1">
Increasing adoption of JAK inhibitors (such as JAKAFI) and the development of novel targeted agents are enhancing disease management and expanding treatment options.
</li>
<li dir="ltr" aria-level="1">
The increasing prevalence of Polycythemia Vera, particularly among aging populations, is contributing to a steady rise in the patient pool across key markets.
</li>
</ul>
<h3 dir="ltr">Polycythemia Vera Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Despite advancements, curative treatment remains elusive. Current therapies primarily manage symptoms and progression, which limits long-term market growth.
</li>
<li dir="ltr" aria-level="1">
The high cost of JAK inhibitors and other novel therapies can restrict access, especially in markets with budget-constrained healthcare systems or limited reimbursement.
</li>
<li dir="ltr" aria-level="1">
Polycythemia Vera often presents with non-specific symptoms, leading to underdiagnosis or misdiagnosis, which hampers timely treatment and overall market potential.
</li>
</ul>
<h3 dir="ltr">Polycythemia Vera Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Incyte/Novartis
</li>
<li dir="ltr" aria-level="1">
PharmaEssentia/AOP Orphan Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Protagonist Therapeutics
</li>
<li dir="ltr" aria-level="1">
Merck (Imago BioSciences)
</li>
<li dir="ltr" aria-level="1">
Italfarmaco
</li>
<li dir="ltr" aria-level="1">
Ionis Pharmaceutical
</li>
<li dir="ltr" aria-level="1">
Silence Therapeutics
</li>
<li dir="ltr" aria-level="1">
Perseus Proteomics
</li>
<li dir="ltr" aria-level="1">
AbbVie
</li>
<li dir="ltr" aria-level="1">
Johnson &amp; Johnson Innovative Medicine
</li>
<li dir="ltr" aria-level="1">
Mabwell (Shanghai) Bioscience and Disc Medicine
</li>
<li dir="ltr" aria-level="1">
GluBio Therapeutics
</li>
</ul>
And others.

Polycythemia Vera Market Infographics

Polycythemia Vera Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape